Lunit to partner with Japanese cancer center on AI initiative
SaveSavedRemoved 0
[ad_1]
The partnership will incorporate the use of Lunit’s Scope, an AI biomarker platform that helps clinicians analyze immunohistochemistry from clinical trials, including the center’s molecular profiling initiatives Scrum-Japan and Monstar-Screen, it said. The objective of the collaboration will be to assess the ability of AI to read biomarkers such as HER2 and PD-L1 and evaluate the performance of new biomarkers such as immune phenotypes, according to Lunit.
Copyright © 2023 AuntMinnie.com
[ad_2]
Go to publisher site for the complete article:
Read More
